Information: Detta är inte den senaste versionen av datamodellen. Du hittar en versionsöversikt till vänster under versioner. Den senaste versionen hittar du här.
Information:
Fel:
ID
34178
Beskrivning
VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT02392455
Länk
https://clinicaltrials.gov/show/NCT02392455
Nyckelord
Versioner (2)
- 2019-01-15 2019-01-15 -
- 2019-05-14 2019-05-14 -
Rättsinnehavare
GSK group of companies
Uppladdad den
15 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Carcinoma, Non-Small-Cell Lung NCT02392455
Eligibility Carcinoma, Non-Small-Cell Lung NCT02392455
- StudyEvent: Eligibility
Similar models
Eligibility Carcinoma, Non-Small-Cell Lung NCT02392455
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
age 18 or older
boolean
ID.2
Item
men and women locally advanced, metastastic and/or recurrent nsclc with adenocarcinoma histology for which vargatef treatment is indicated according to summary of product characteristics (smpc)
boolean
ID.3
Item
after first line therapy; second-line therapy not yet started
boolean
ID.4
Item
standard 21-day-cycles docetaxel treatment according to smpc possible
boolean
ID.5
Item
written informed consent
boolean
ID.6
Item
contraindications according to the smpc of vargatef or docetaxel
boolean
ID.7
Item
more than one systemic therapy for treatment of nsclc in palliative setting
boolean
ID.8
Item
current partcipation in another non-interventional study or a clinical trial
boolean
ID.9
Item
pregnancy
boolean
ID.10
Item
breastfeeding
boolean